Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009-2013

BMC Public Health

Volumn 14, Issue 1, 2014, Pages

  Ladner, Joël ^a   Besson, Marie Hélène ^b   Rodrigues, Mariana ^b   Audureau, Etienne ^c   Saba, Joseph ^b  

^a HÔPITAL CHARLES NICOLLE   (France)

^b Axios International   (France)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

Developing countries; Human papillomavirus vaccine, type 16 L1, 18; Immunization uterine cervical neoplasms; Preventive health services; Program evaluation; Vaccination; Vaccines

Indexed keywords

HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; WART VIRUS VACCINE;

ADOLESCENT; ADULT; CHILD; DEVELOPING COUNTRY; ECONOMICS; EVALUATION STUDY; FEMALE; HUMAN; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATIENT ATTITUDE; PREVENTIVE HEALTH SERVICE; PROGRAM EVALUATION; STATISTICS AND NUMERICAL DATA; UTERINE CERVICAL NEOPLASMS;

ADOLESCENT; ADULT; CHILD; DEVELOPING COUNTRIES; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; PROGRAM EVALUATION; UTERINE CERVICAL NEOPLASMS;

EID: 84904202807     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-14-670     Document Type: Article

References (48)

1. Estimate of worldwide burden of in 2008. Globocan 2008. Ferlay J, Shin H, Baray F, Forman D, Mathers C, Parkin DM, Int J Cancer 2010 127 2893 2917 10.1002/ijc.25516 21351269
2. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF, Int J Cancer 2004 109 418 424 10.1002/ijc.11719 14961581 (Pubitemid 38252771)
3. Human papillomavirus and cervical cancer. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC, Lancet 2013 382 889 899 10.1016/S0140-6736(13)60022- 7 23618600
4. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N, J Pathol 1999 189 12 19 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F 10451482 (Pubitemid 29406813)
5. Epidemiologic classification of human papillomavirus types associated with cervical cancer. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group, N Engl J Med 2003 348 518 527 10.1056/NEJMoa021641 12571259 (Pubitemid 36159887)
6. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. Quadrivalent V, N Engl J Med 2007 356 1915 1927 17494925
7. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G, HPV PATRICIA study group, Lancet 2007 369 2161 2170 10.1016/S0140-6736(07)60946-5 17602732 (Pubitemid 46977438)
8. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group, Lancet 2009 374 301 314 10.1016/S0140-6736(09)61248-4 19586656
9. Evaluating human papillomavirus vaccination programs. Taira AV, Neukermans CP, Sanders GD, Emerg Inf Dis 2004 10 1915 1923 10.3201/eid1011. 040222 (Pubitemid 39458555)
10. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh G, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E, Brit J Cancer 2006 95 1459 1466 10.1038/sj.bjc.6603469 17117182 (Pubitemid 44863348)
11. An assessment of the readiness for introduction of the HPV vaccine in Uganda. Katahoire RA, Jitta J, Kivumbi G, Murokora D, Arube WJ, Siu G, Arinaitwe L, Bingham A, Mugisha E, Tsu V, LaMontagne DS, Afr J Reprod Health 2008 12 159 172 19435020
12. Preparing for HPV vaccination in South Africa: key challenges and opinions. Harries J, Moodley J, Barone MA, Mall S, Sinanovic E, Vaccine 2009 27 38 44 10.1016/j.vaccine.2008.10.033 18977271
13. HPV vaccine acceptability among Kenyan women. Becker-Dreps S, Otieno WA, Brewer NT, Agot K, Smith JS, Vaccine 2012 28 4864 4867
14. Introducing HPV vaccine in developing countries-key challenges and issues. Agosti JM, Goldie SJ, N Engl J Med 2007 356 1908 1910 10.1056/NEJMp078053 17494923 (Pubitemid 46740300)
15. Benefits, cost requirements and cost-effectiveness of the HPV16, 18 vaccine for cervical cancer prevention in developing countries: policy implications. Goldie SJ, O'Shea M, Diaz M, Kim SY, Reprod Health Matters 2008 32 86 96
16. Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean. Franco EL, Tsu V, Herrero R, Lazcano-Ponce E, Hildesheim A, Munoz N, Murillo R, Sánchez GI, Andrus JK, Vaccine 2008 26 Suppl11 88 L95 18945406
17. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, Janmohamed A, Kumakech E, Mosqueira NR, Nguyen NQ, Paul P, Tang Y, Minh TH, Uttekar BP, Jumaan AO, J Bull World Health Organ 2011 89 821 830B 10.2471/BLT.11.08986
18. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Brewer NT, Fazekas KI, Prev Med 2007 45 107 114 10.1016/j.ypmed.2007.05. 013 17628649 (Pubitemid 47348081)
19. Health systems and immunization financing for human papillomavirus vaccine introduction in low-resource settings. Biellik R, Levin C, Mugisha E, LaMontagne DS, Bingham A, Kaipilyawar S, Gandhi S, Vaccine 2009 44 6203 6209
20. Sociocultural issues in the introduction of human papillomavirus vaccine in low-resource settings. Bingham A, Drake JK, LaMontagne DS, Arch Pediatr Adolesc Med 2009 163 455 461 10.1001/archpediatrics.2009.50 19414692
21. HPV vaccine acceptability in Ghana, West Africa. Coleman MA, Levison J, Sangi-Haghpeykar H, Vaccine 2011 29 3945 3950 10.1016/j.vaccine.2011.03.093 21481327
22. A cross-sectional study of HPV vaccine acceptability in Gaborone, Botswana. DiAngi YT, Panozzo CA, Ramogola-Masire D, Steenhoff AP, Brewer NT, PLoS One 2011 6 10 25481 10.1371/journal.pone.0025481 22039413
23. Parental acceptance of human papillomavirus (HPV) vaccination in Indonesia: a cross-sectional study. Jaspers L, Budiningsih S, Wolterbeek R, Henderson FC, Peters AA, Vaccine 2011 29 7785 7793 10.1016/j.vaccine.2011.07.107 21821079
24. Chapter 15: HPV vaccine use in the developing world. Kane MA, Sherris J, Coursaget P, Aguado T, Cutts F, Vaccine 2006 24 Suppl 3S3 132 139
25. Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review. Louie KS, de Sanjose S, Mayaud P, Trop Med Int Health 2009 14 1287 1302 10.1111/j.1365-3156.2009.02372.x 19772550
26. Chapter 25: Education, training, and communication for HPV vaccines. Sherris J, Friedman A, Wittet S, Davies P, Steben M, Saraiya M, Vaccine 2006 24 Suppl 3 210 218
27. Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospects. Wigle J, Coast E, Watson-Jones D, Vaccine 2013 31 3811 3817 10.1016/j.vaccine.2013.06. 016 23777956
28. Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Wright TC, Bosch FX, Franco EL, Cuzick J, Schiller JT, Garnett GP, Meheus A, Vaccine 2006 24 Suppl 3 251 261
29. Human papillomavirus vaccines: WHO position paper. WHO, WHO Weekly Epidemiol Record 2009 84 117 132
30. The need for targeted implementation research to improve coverage of basic vaccines and introduction of new vaccines. Arora NK, Lal AA, Hombach JM, Santos JI, Bhutta ZA, Sow SO, Greenwood B, Vaccine 2008 31 Suppl 2 129 B136
31. Assessment of eight HPV vaccination programs implemented in lowest income countries. Ladner J, Besson MH, Hampshire R, Tapert L, Chirenje M, Saba J, BMC Public Health 2012 12 370 10.1186/1471-2458-12-370 22621342
32. Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F, J Bull World Health Organ 2012 90 623 628 10.2471/BLT.11.097253
33. Implementation of human papillomavirus immunization in the developing world. Kane MA, Serrano B, de Sanjose S, Wittet S, Vaccine 2012 30 Suppl5 192 F200 23199963
34. A school-based human papillomavirus vaccination program in barretos, Brazil: final results of a demonstrative study. Fregnani JH, Carvalho AL, Eluf-Neto J, Ribeiro Kde C, Kuil Lde M, Da Silva TA, Rodrigues SL, Mauad EC, Longatto-Filho A, Villa LL, PLoS One 2013 8 62647 10.1371/journal.pone.0062647 23638130
35. Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies. Watson-Jones D, Baisley K, Ponsiano R, Lemme F, Remes P, Ross D, Kapiga S, Mayaud P, de Sanjosé S, Wight D, Changalucha J, Hayes R, J Inf Dis 2012 206 678 686 10.1093/infdis/jis407
36. UNICEF, Progress for Children 2007-Primary Education New York: United Nations Children's Fund 2007 Available at: http://www.unicef.org/ progressforchildren/2007n6/files/Progress-for-Children-No.-6.pdf (last accessed May 2014)
37. Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts. Jit M, Levin C, Brisson M, Levin A, Resch S, Berkhof J, Kim J, Hutubessy R, BMC Med 2013 11 23 10.1186/1741-7015-11-23 23363734
38. Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models. Jit M, Demarteau N, Elbasha E, Ginsberg G, Kim J, Praditsitthikorn N, Sinanovic E, Hutubessy R, BMC Med 2011 9 54 10.1186/1741-7015-9-54 21569406
39. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania. Quentin W, Terris-Prestholt F, Changalucha J, Soteli S, Edmunds WJ, Hutubessy R, Ross DA, Kapiga S, Hayes R, Watson-Jones D, BMC Med 2012 10 137 10.1186/1741-7015-10-137 23148516
40. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool. Hutubessy R, Levin A, Wang S, Morgan W, Ally M, John T, Broutet N, BMC Med 2012 10 136 10.1186/1741-7015-10-136 23146319
41. Delivery costs of human papillomavirus vaccination of young adolescent girls in Peru, Uganda and Viet Nam. Levin CE, Van Minh H, Odaga J, Sari Rout S, Nguyen Thi Ngoc D, Menezes L, Araujo MA, LaMontagne DS, Bull World Health Organ 2013 91 595 920
42. Effective health interventions for adolescents that could be integrated with human papillomavirus vaccination programs. Broutet N, Lehnertz N, Mehl G, Camacho AV, Bloem P, Chandra-Mouli V, Ferguson J, Dick B, J Adolesc Health 2013 53 6 13 10.1016/j.jadohealth.2013.02.022 23643336
43. Cost-effectiveness of human papillomavirus vaccination in low and middle-income countries: a systematic review. Fesenfeld M, Hutubessy R, Jit M, Vaccine 2013 31 3786 3804 10.1016/j.vaccine.2013.06.060 23830973
44. Strategies to vaccinate against cancer of the cervix: feasibility of a school-based HPV vaccination program in Peru. Penny M, Bartolini R, Mosqueira NR, LaMontagne DS, Mendoza MA, Ramos I, Winkler JL, Villafana J, Janmohamed A, Jumaan AO, Vaccine 2011 29 5022 5030 10.1016/j.vaccine.2011.04.078 21609748
45. High uptake of Gardasil vaccine among 9-12 years-old schoolgirls participating in an HPV vaccination demonstration project in KwaZulu-Natal, South Africa. Moodley I, Tathiah N, Mubaiwa V, Denny L, S Afr Med J 2013 105 318 321
46. Human papilloma virus vaccination in Nepal: an initial experience in Nepal. Singh Y, Shah A, Singh M, Verma S, Shrestha BM, Vaida P, Nakarmi RP, Shrestha SB, Asian Pac J Cancer Prev 2010 11 615 617 21039025
47. Acceptance patterns and decision-making for human papilloma virus vaccination among parents in Vietnam: an in-depth qualitative study post-vaccination. Cover JK, Nghi NQ, LaMontagne DS, Huyen DT, Hien NT, Nga T, BMC Public Health 2012 12 629 10.1186/1471-2458-12-629 22877158
48. Human papillomavirus vaccination in adolescence. Russell M, Raheja V, Jaiyesimi R, Perspect Public Health 2013 133 320 324 10.1177/1757913913499091 24006173